Indeed, the RAS/RAF/MEK/ERK signaling cascade, key in the physiological response to estradiol, has been found to be frequently over activated in various types of cancers, although mutations in this pathway are not usually described in breast cancer. This evidence concerns the gene MAP2K7 and cancer.